Literature DB >> 9440025

Growth factors in gliomas: antisense and dominant negative mutant strategies.

J W Campbell1, I F Pollack.   

Abstract

Antisense and dominant negative mutant strategies were developed as 'magic bullets' to suppress the function of a particular gene while preserving the remaining cellular activities. While experience with these techniques has dispelled some of the 'magic', these strategies remain useful for understanding the function of particular gene products. Antisense strategies involve the administration of either a synthetic oligodeoxynucleotide or a plasmid construct which produces a sequence that is complementary to the DNA or mRNA of the gene of interest. Antisense binding should inhibit transcription or translation of the gene, and thus decrease synthesis of the protein for which the gene encodes. Conversely, dominant negative mutations inhibit activity of a gene product by encoding for a second protein which suppresses the function of the gene of interest. For example, a single mutant subunit in a multimeric protein might allow normal assembly of the protein while inhibiting its activity. The use of these techniques for investigating the role of various growth factor pathways in glial neoplasia and their potential therapeutic applications are reviewed below.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9440025     DOI: 10.1023/a:1005820701709

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  52 in total

Review 1.  Anti-sense oligodeoxynucleotides--promises and pitfalls.

Authors:  C A Stein
Journal:  Leukemia       Date:  1992-10       Impact factor: 11.528

2.  Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways.

Authors:  I F Pollack; M S Randall; M P Kristofik; R H Kelly; R G Selker; F T Vertosick
Journal:  J Neurosurg       Date:  1991-08       Impact factor: 5.115

3.  Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I.

Authors:  J Trojan; B K Blossey; T R Johnson; S D Rudin; M Tykocinski; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

4.  Antisense has growing pains.

Authors:  T Gura
Journal:  Science       Date:  1995-10-27       Impact factor: 47.728

5.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues.

Authors:  A M Belikova; V F Zarytova; N I Grineva
Journal:  Tetrahedron Lett       Date:  1967-09       Impact factor: 2.415

7.  Cells transfected with the basic fibroblast growth factor gene fused to a signal sequence are invasive in vitro and in situ in the brain.

Authors:  S Gately; A M Tsanaclis; S Takano; M Klagsbrun; S Brem
Journal:  Neurosurgery       Date:  1995-04       Impact factor: 4.654

8.  The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

Authors:  P Jachimczak; U Bogdahn; J Schneider; C Behl; J Meixensberger; R Apfel; R Dörries; K H Schlingensiepen; W Brysch
Journal:  J Neurosurg       Date:  1993-06       Impact factor: 5.115

9.  Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes.

Authors:  R S Morrison
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

10.  Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells.

Authors:  S M Shamah; C D Stiles; A Guha
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

View more
  1 in total

1.  Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression.

Authors:  M M Mueller; C C Herold-Mende; D Riede; M Lange; H H Steiner; N E Fusenig
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.